The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy alone in the treatment of cancer patient:A protocol for systematic review

Suyue Zhao, Tao Fang, Yao Li, Ying Zheng, Ling Zhang, Kexiang Zhu2020 · DOI

This document outlines a formal protocol for a systematic review and meta-analysis. As it is a protocol, it describes the intended methodology for a study that has not yet been completed.

Protocol Spotlight: Evaluating PARP Inhibitors in Combination Therapy

TL;DR

Researchers from Lanzhou University have published a roadmap for a systematic review to determine if adding PARP inhibitors to standard chemotherapy actually helps cancer patients live longer. By aggregating data from Phase 2 and 3 clinical trials across all cancer types, the study aims to clarify whether this combination therapy offers a significant survival advantage or simply increases the burden of toxic side effects.

What Problem Does This Paper Address?

In the last decade, Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a powerful tool in the oncology arsenal. These drugs work by blocking a specific enzyme that helps repair damaged DNA; in cancer cells—which already have DNA repair defects—this leads to cell death.

While PARP inhibitors have seen great success as a "monotherapy" (used alone), the oncology community is currently grappling with a critical question: Is more better? Combining PARP inhibitors with traditional chemotherapy seems logical—the chemo damages the DNA, and the PARP inhibitor prevents the repair. However, this "double hit" can also be significantly more toxic to the patient. Currently, there is no high-level consensus on whether the efficacy gains of this combination outweigh the adverse effects across different types of cancer. This protocol sets the stage to provide that missing bird's-eye view.

Methods

The authors outline a rigorous meta-analysis framework following the Cochrane Intervention Systematic Review Manual. Key methodological features include:

  • Search Strategy: A comprehensive search of major medical databases (PubMed, EMBASE, Web of Science, Cochrane Library) and clinical trial registries (ClinicalTrials.gov, WHO ICTRP).
  • Inclusion Criteria: The study is restricted to Phase 2 and Phase 3 Randomized Controlled Trials (RCTs). This ensures the data comes from high-quality, comparative studies rather than anecdotal or early-stage observations.
  • Statistical Analysis: The team will use RevMan 5.3 software. They plan to use Random Effects Models to synthesize data, which is a sophisticated choice that accounts for the "heterogeneity" (differences) expected when looking at various cancer types and drug dosages.
  • Bias Control: To ensure objectivity, two researchers will independently screen articles and extract data, with a third party acting as an arbitrator for any disagreements.

Datasets

As a systematic review protocol, this paper does not introduce a new experimental dataset. Instead, it defines the "population" of data it will draw from:

  • Primary Sources: Peer-reviewed literature from the four databases mentioned above.
  • Trial Registries: Ongoing or unpublished data from ClinicalTrials.gov, ISRCTN Registry, and the WHO International Clinical Trials Registration Platform.
  • Scope: All cancer patients regardless of country, gender, age, race, or specific tumor type.

Key Insights and Ideas

  • The "All-Comers" Approach: Unlike many systematic reviews that focus strictly on one disease (like ovarian or breast cancer), this protocol is designed to include all cancer types. This allows the researchers to identify if PARP inhibitor synergy is a universal biological phenomenon or if it is highly dependent on the specific tumor environment.
  • Focus on "Time-Event" Data: The protocol emphasizes Hazard Ratios (HR) for Overall Survival and Progression-Free Survival. This is more robust than simple "success/failure" counts because it accounts for when events happen during the treatment journey.
  • Addressing the "Toxicity Trade-off": The authors have pre-defined a specific list of adverse effects to track, including neutropenia (low white blood cell count) and thrombocytopenia (low platelets). This suggests a primary goal is to determine if the combination therapy is "too harsh" for the average patient.

Key Results

Not discussed in the paper. As this is a protocol, the results will be generated once the systematic review is conducted according to these outlined steps. The authors state that at the time of submission, "The review has not yet started."

Limitations and Future Work

The authors acknowledge a few inherent challenges in their planned work:

  • Heterogeneity: Because they are including different types of tumors and different chemotherapy regimens, the "noise" in the data might be high. They plan to address this through subgroup analysis (breaking the data down by tumor type, age, and gender).
  • Publication Bias: There is always a risk that trials with negative results aren't published. The authors plan to use funnel charts and Begg’s/Egger’s tests to statistically detect if they are missing "failed" studies that would change their conclusions.
  • Future Directions: Once completed, this study will likely serve as a clinical guideline, helping oncologists decide which patients are the best candidates for PARP inhibitor combinations and which should stick to standard care to avoid unnecessary toxicity.

Summary updated

Abstract

The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy
BibTeX
@misc{zhao2020efficacy,
  author = {Suyue Zhao and Tao Fang and Yao Li and Ying Zheng and Ling Zhang and Kexiang Zhu},
  title = {{The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy alone in the treatment of cancer patient:A protocol for systematic review}},
  year = {2020},
  doi = {10.37766/inplasy2020.9.0087},
}
Figure